Current Hypertension Reviews最新文献

{"title":"Evaluating Mean Blood Pressure as a Potential Therapeutic Target in Systolic Hypertension with Too Low Baseline Diastolic Blood Pressure.","authors":"Goran Koraćević, Milovan Stojanović","doi":"10.2174/0115734021478003260713114540","DOIUrl":"https://doi.org/10.2174/0115734021478003260713114540","url":null,"abstract":"<p><strong>Introduction: </strong>Isolated systolic hypertension (ISH) has a high mortality rate and a high prevalence of hypertension-mediated organ damage (HMODs). The aims of this paper are: (1) to search arterial hypertension (HTN) guidelines to determine whether mean blood pressure (BP) is mentioned as a treatment target for ISH patients with too-low pre-treatment dBP, and (2) to analyze whether there is a rationale for suggesting mean BP as a potential antihypertensive treatment target.</p><p><strong>Methods: </strong>We performed a search for HTN guidelines in Scopus, the Medline database, Springer Nature, Cambridge University Press, Oxford University Press, and Wiley-Blackwell. The scholarly search engine Google Scholar was also used.</p><p><strong>Results: </strong>Mean BP is already used to guide BP treatment in numerous settings, mostly in intensive care units, and guidelines recognize that mean BP can be used in several clinical scenarios to evaluate antihypertensive treatment. However, mean BP is not mentioned in half of the guidelines, and none of the 40 HTN guidelines mention mean BP as a chronic treatment target in ISH.</p><p><strong>Discussion: </strong>The main finding of this narrative review is that the problem of ISH with a too-low baseline dBP has been clearly identified but remains unresolved. This paper does not offer a definitive answer but presents an initial approach to addressing the problem.</p><p><strong>Conclusion: </strong>The problem of ISH with too-low dBP is clinically relevant, and such patients are difficult to treat. We propose mean BP for investigation and evaluation as a means of adjusting the intensity of antihypertensive treatment in large patient populations with ISH and too-low dBP.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148608446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Nurses in Hypertension Management: A Bibliometric Analysis.","authors":"Murat Şimşek, Gülay Demir, Hatice Tel Aydin","doi":"10.2174/0115734021455642260706053806","DOIUrl":"https://doi.org/10.2174/0115734021455642260706053806","url":null,"abstract":"<p><strong>Introduction: </strong>Hypertension is a chronic health problem affecting billions of people worldwide. Consequently, numerous studies have been conducted in the nursing field focusing on hypertension management. This study aims to conduct a bibliometric analysis of studies published between 2014 and 2024.</p><p><strong>Methods: </strong>A detailed literature review was conducted using the RStudio Biblioshiny and VOSviewer software packages. A total of 724 studies published in journals indexed in the Scopus database were included in the analysis.</p><p><strong>Results: </strong>Bibliometric data indicate that nursing research increased in parallel with the growing demand for nursing care during the COVID-19 pandemic. Furthermore, studies have focused on hypertension management across diverse patient populations.</p><p><strong>Discussion: </strong>Nursing research has shown a steady increase over the years, indicating the growing importance that nurses place on hypertension management. The United States' leadership in research can be attributed to its strong research capacity and advanced healthcare system. Furthermore, the prominence of COVID-19 as a topic highlights its significant impact on nursing care.</p><p><strong>Conclusion: </strong>This study underscores the indispensable role of nurses in the management of hypertension. These findings can facilitate a better understanding of the current state of the literature and provide researchers with foundational data to guide future original studies on hypertension management.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148521137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is this the Time to Prioritize Risk Factors Based on their Contributions to Outcomes for Effective Prevention and Treatment?","authors":"Kei Nakajima, Airi Sekine","doi":"10.2174/0115734021468336260410091802","DOIUrl":"https://doi.org/10.2174/0115734021468336260410091802","url":null,"abstract":"","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148279171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Benefits Beyond Hypertension Control: Current and Evolving Treatment Strategies for Prevention of Cardiovascular Diseases.","authors":"Abhijit Taraphder, Alan Almeida, Sameer Dani, Sandeep Bansal, Jayagopal Pathiyil Balagopalan, Arpandev Bhattacharyya, Abdul Hamid Zargar, Subhankar Chowdhury, Shailaja Kale, Nilakshi Deka, Dinesh Jiwane, Sanjay Jain","doi":"10.2174/0115734021435628260415113327","DOIUrl":"https://doi.org/10.2174/0115734021435628260415113327","url":null,"abstract":"<p><strong>Introduction: </strong>Cardiovascular Disease (CVD) continuum often begins with uncontrolled hypertension, progressing through structural/functional impairment of the cardiovascular system and atherosclerosis toward myocardial infarction, stroke, and cardiovascular death. Hypertension affects over one billion people globally, yet less than half have been diagnosed and received treatment. Suboptimal management of elevated Blood Pressure (BP) remains a challenge across low- and middle-income countries, including India. This review outlined the CVD continuum associated with hypertension, along with guideline-recommended new paradigm and emerging/ novel approaches for managing hypertension and CVD risk.</p><p><strong>Methods: </strong>Data from PubMed and Google Scholar have been extracted using the following search terms: cardiovascular disease continuum, hypertension management, cardiovascular risk reduction, anti-hypertensive drugs, non-pharmacological approach, guideline recommendations, evolving strategies, and herbal medicine.</p><p><strong>Results: </strong>A total of 101 articles, published between 2004 and 2025, were included, comprising 20 systematic reviews and meta-analyses, 27 trials, 24 research articles, 10 guidelines, 18 review articles, and 2 editorials. The evidence and guideline recommendations on clinical and therapeutic considerations for effective management of hypertension have been discussed.</p><p><strong>Discussion: </strong>Several guidelines preferred initial treatment (BP threshold: 130-140/80-90 mmHg) with monotherapy (angiotensin-converting enzyme inhibitor/ angiotensin-receptor blocker/ calcium channel blocker/ diuretic/ beta-blocker) or combination therapy of two or more medications with complementary mechanisms (in a single-pill) for managing cardiovascular complications and improving treatment adherence. Beta-blockers are thought to be recommended for people with cardiovascular complications, but their effect in reducing stroke, infarction, and mortality is inferior to other drug classes. The addition of an anti-aldosterone drug to the first-line therapy is recommended for managing resistant hypertension. Recent pharmacological advancements, including anti- aldosterone agents, non-steroidal mineralocorticoid receptor antagonists, endothelin receptor antagonists, etc., have demonstrated remarkable efficacy in BP reduction with tolerable safety profiles.</p><p><strong>Conclusion: </strong>A holistic management strategy integrating standard medical care along with lifestyle modifications, herbal medicines, and digital health platforms could enhance treatment adherence and interrupt the CVD continuum.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148273303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oxidative Stress and Antioxidants in Hypertension: A Review on Mechanisms and Clinical Challenges.","authors":"Mostafa Cheraghi, Fatemeh Hatami, Mostafa Dehghani, Solmaz Jabarzare, Ali Rafieian, Hosna Cheraghi, Amirhosein Cheraghi, Mehrnoosh Sedighi, Mahmoud Rafieian-Kopaei","doi":"10.2174/0115734021430579260608102038","DOIUrl":"https://doi.org/10.2174/0115734021430579260608102038","url":null,"abstract":"<p><p>Hypertension remains a major global health burden, with many patients exhibiting resistance to standard antihypertensive regimens. Oxidative stress-driven by reactive oxygen species (ROS) generated through the activation of the renin-angiotensin-aldosterone system (RAAS)-is increasingly recognized as a potential contributor to vascular dysfunction, inflammation, and elevated blood pressure. This review aims to synthesize current mechanistic evidence on the role of oxidative stress in hypertension and to evaluate clinical data on whether antioxidant interventions can mitigate hypertension and its associated organ damage. Preclinical and animal studies provide strong support for a causal link between elevated ROS, redox-sensitive signaling, and increased blood pressure, endothelial dysfunction, and end-organ injury. However, clinical trials investigating antioxidant therapies have produced inconsistent results. Differences in antioxidant type, dosage, timing, and study populations likely contribute to this heterogeneity. The discrepancy between robust mechanistic data and equivocal clinical outcomes underscores translational challenges. While oxidative stress appears to play a central role in hypertension pathophysiology, current evidence does not support the routine use of antioxidants as antihypertensive therapy. Future research should focus on welldesigned trials with standardized antioxidant regimens, stratified patient populations, and long-term follow-up to clarify whether targeting redox imbalance can yield meaningful clinical benefits.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148266552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resistant Hypertension: Pathophysiology, Diagnostic Approaches, and Emerging Therapeutic Strategies.","authors":"Manjappa Mahadevappa, Himabindu Jayaprakash Narayan, Bharath Raj Srinivasan","doi":"10.2174/0115734021429097260401053734","DOIUrl":"https://doi.org/10.2174/0115734021429097260401053734","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Resistant Hypertension (RH) is defined as Blood Pressure (BP) that remains uncontrolled despite the concurrent use of three antihypertensive agents from different classes, including a diuretic. This review examines the pathophysiology, diagnostic criteria, and emerging therapeutic strategies in RH management, with an emphasis on current clinical challenges and future directions.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This article is a narrative (non-systematic) review. PubMed and Scopus were searched for \"English language\" literature from January 2000 through June 2025, using terms including \"resistant hypertension\", \"apparent treatment resistant hypertension\", \"renal denervation\", \"aldosterone\", and \"secondary hypertension\". Guidelines, randomized controlled trials, and systematic reviews/meta-analyses directly relevant to the pathophysiology, diagnosis, and treatment of resistant hypertension were prioritized. Additional landmark observational studies were included when considered clinically informative.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;RH affects up to 10% of hypertensive patients globally, with higher prevalence in those with chronic kidney disease and obstructive sleep apnea. Misdiagnosis due to pseudo-resistance and poor medication adherence remains prevalent. Pathophysiology involves complex mechanisms, including sympathetic overactivity, dysregulation of the RAAS, and aldosterone excess. Diagnostic confirmation includes excluding pseudo-resistance and evaluating for secondary causes. Lifestyle modifications remain foundational. Mineralocorticoid receptor antagonists, aldosterone synthase inhibitors, renal denervation, and baroreceptor therapies show promise in treating cases resistant to other therapies.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Discussion: &lt;/strong&gt;While conventional pharmacotherapy remains the cornerstone, inadequate BP control in RH necessitates a deeper understanding of underlying mechanisms and adherence assessment. Device-based approaches and emerging agents, such as zilebesiran and aprocitentan, may hold promise in revolutionizing RH management but require further validation. Limitations include a lack of large-scale comparative trials and accessibility concerns in low-resource settings.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Resistant hypertension represents a multifactorial condition requiring a multidimensional diagnostic and therapeutic approach. Integrating lifestyle changes, optimized pharmacotherapy, and emerging options, including aldosterone synthase inhibition, dual endothelin receptor antagonism, small-interfering RNA strategies, and refined device-based approaches, offers incremental BP reductions in carefully selected patients. The synthesis emphasizes a pragmatic, stepwise strategy that couples adherence and secondary cause assessment with evidence-based pharmacologic intensification (notably mineralocorticoid receptor antagonists) and selective device therapy. This integrated approach may be critical for a","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":0.8,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147677475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Potential of Phytoconstituents in the Management of Hypertension.","authors":"Tanya Gupta, Rishabh Chalotra, Randhir Singh, Thakur Gurjeet Singh","doi":"10.2174/0115734021428187260122072751","DOIUrl":"https://doi.org/10.2174/0115734021428187260122072751","url":null,"abstract":"<p><p>Hypertension poses a significant global health burden due to its prevalence and serves as a major risk factor for cardiovascular diseases (CVDs) such as stroke, heart failure, myocardial infarction and renal dysfunction. Current clinical guidelines emphasize pharmacological management and lifestyle modifications. Despite the availability of effective pharmacological therapies, including diuretics, beta-blockers, calcium channel blockers, and ACE (angiotensin-converting enzyme) inhibitors, hypertension control remains suboptimal due to side effects, limited patient adherence, and the inability of single-target drugs to address the multifaceted nature of the disease. This has fuelled interest in herbal therapies as safer and more holistic alternatives, leveraging the therapeutic potential of plant-derived phytoconstituents. Medicinal plants are rich in bioactive phytoconstituents such as flavonoids, alkaloids, glycosides, coumarins, tannins, phenolic acids, and terpenes. These compounds exhibit diverse antihypertensive effects, including ACE inhibition, calcium channel blockade, vasodilation, diuretic action, and antioxidant activity. Flavonoids enhance nitric oxide (NO) bioavailability, improving endothelial function and reducing vascular resistance. Alkaloids modulate calcium channels and sympathetic activity, while phenolic acids and terpenes exhibit RAAS modulation and oxidative stress reduction. Preclinical and clinical studies have demonstrated the efficacy of these phytoconstituents in treating hypertension via various mechanisms. Advancements in research have highlighted the potential of these compounds as adjuvant therapies, offering synergistic effects when combined with standard antihypertensive treatments. Such combinations may reduce the required doses of synthetic drugs, minimize side effects, and enhance patient compliance.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":0.8,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147616915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gene-Targeted Hypertension Therapy. Is It Time for Indonesia?","authors":"Agil Wahyu Wicaksono, Tuko Srimulyo, Rizky Amalia Siregar, Brilliant Cahya Puspasari, Yusuf Ryadi","doi":"10.2174/0115734021427931260121101602","DOIUrl":"https://doi.org/10.2174/0115734021427931260121101602","url":null,"abstract":"<p><p>Hypertension remains a significant global health challenge due to its high preva-lence and complications worldwide. The complex interactions between genetic, environmen-tal, and lifestyle factors mean that current pharmacological treatments for hypertension have limited long-term effectiveness, which can be characterized as refractory hypertension. Tar-geted gene therapy offers a revolutionary approach by addressing the underlying genetic mech-anisms of hypertension, providing a personalized, potentially curative solution with fewer side effects. In Indonesia, the implementation of targeted gene therapy for hypertension faces sig-nificant challenges due to limited genomic infrastructure, high costs of genetic testing, and low awareness among healthcare professionals and the public. This genetic approach is still limited to research or rare monogenic cases and has not been implemented routinely in clinical prac-tice. Ethical, cultural, and religious considerations also continue to limit public acceptance of this genetic intervention, in addition to the lack of a clear legal and regulatory framework gov-erning gene therapy and the protection of genetic data. Nevertheless, the Indonesian govern-ment, through the Biomedical Genome-based Science Initiative (BGSi), has begun to initiate medical integration, which aims to develop population-specific genomic databases, improve precision medicine, and build national capacity for future implementation of gene-based ther-apies, including for hypertension. This literature review aims to comprehensively examine hy-pertension and gene therapy, synthesizing global evidence on genetic mechanisms, therapeutic advances, and implementation challenges, while outlining future opportunities and strategies for integrating gene-based medicine into the Indonesian health care system.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":0.8,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147515603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What is the Target Resting Heart Rate in Guidelines on Hypertension?","authors":"Goran Koracevic, Milovan Stojanovic, Miloje Tomasevic, Marija Zdravkovic, Dragan Lovic, Suzana Otasevic, Dragan Simic, Tomislav Kostic, Sonja Dakic","doi":"10.2174/0115734021424078251219091427","DOIUrl":"https://doi.org/10.2174/0115734021424078251219091427","url":null,"abstract":"<p><p>It is widely recognized that not only high blood pressure (BP) but also increased resting heart rate (RHR) impairs prognosis in patients with arterial hypertension (HTN). This study aims to answer 5 questions regarding the guidelines on HTN: 1. 'Is the significance of high RHR in HTN acknowledged?'; 2. 'Is there a recommendation to decrease RHR in chronic antihypertensive treatment?'; 3. 'Which antihypertensive medication is preferred to diminish high RHR in HTN patients?' 4. 'What is the treatment threshold value of RHR in patients with HTN?' and 5. 'Is there a recommendation for target RHR in chronic treatment of HTN?'. The significance of RHR and the treatment approach to it are scarcely mentioned in the key publi-cations-the guidelines on HTN-and there is no obvious firm argument to omit recommen-dations related to threshold and target RHR in HTN patients. On the contrary, there are at least five (major) reasons for addressing increased RHR in HTN guidelines. The vast majority of HTN guidelines do not acknowledge the significance of RHR elevation (as a cardiovascular risk factor). This discrepancy affects as much as 30-38% of the hypertensive population (that is, global > 1.28 billion adults - according to the World Health Organization). We highlight the need for improvement in the forthcoming guidelines that (in the current versions) do not explain the importance of RHR in HTN. Additional investigations are needed to confirm whether reducing high resting heart rate in HTN patients improves prognosis.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":0.8,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147515647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relation between Uric Acid-to-albumin Ratio and Hypertension in Non-alcoholic Fatty Liver Disease.","authors":"Nessren Mohamed Bahaa El Deen Mohamed, Sara Mohammed Foaud Hussein, Noura Ali Ghazy Zidan, Samah M Akab, Shaymaa A Mohammed, Radwa M Fath Allah, Maha M Esmail, Eman A El-Mnakhly, Aya A Eldamanhory, Heba Shoman","doi":"10.2174/0115734021422803260202113520","DOIUrl":"https://doi.org/10.2174/0115734021422803260202113520","url":null,"abstract":"<p><strong>Introduction/objective: </strong>Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, with a rapid increase in cases worldwide. NAFLD has recently emerged as an important driving force in the development and progression of hypertension. The uric acid-toalbumin ratio (UAR) is a new marker of cardiovascular disease. The present study aimed to assess the relationship between UAR and hypertension in patients with NAFLD.</p><p><strong>Methods: </strong>The present prospective case-control study included 200 NAFLD patients. In addition, there were 100 age- and sex-matched controls. NAFLD was diagnosed on the basis of evidence of fatty liver infiltration shown by ultrasound in the absence of significant alcohol intake (maximum 30 g/day in males and 20 g/day in females) and other possible causes of fatty liver disease. Hypertension was diagnosed according to the recommendations of the 2020 International Society of Hypertension Global Hypertension Practice Guidelines. UAR was calculated by dividing uric acid levels (mg/dL) by serum albumin levels (g/dL). Group comparisons were performed using the independent samples t-test for continuous variables and the chi-square test for categorical variables. Binary logistic regression was used for multivariate analysis.</p><p><strong>Results: </strong>Comparison between patients and controls revealed that patients had significantly higher UAR than controls (1.46 ± 0.35 versus 1.34 ± 0.28, p=0.001). The NAFLD group included 71 hypertensive patients (35.5 %). Hypertensive patients had significantly higher UAR than normotensive counterparts (1.56 ± 0.38 versus 1.41 ± 0.32 mg/g, p=0.005). Binary logistic analysis identified obesity (OR (95% CI): 9.68 (3.92-23.92), p<0.001), diabetes mellitus (DM) (OR (95% CI): 3.08 (1.56- 6.12), p=0.001) and elevated UAR (OR (95% CI): 11.12 (3.62-34.19), p<0.001) as significant predictors of hypertension in the studied patients in multivariate analysis.</p><p><strong>Discussion: </strong>The present study identified the trio of obesity, diabetes mellitus, and elevated UAR as predictors of hypertension in multivariate analysis, consistent with multiple previous reports.</p><p><strong>Conclusions: </strong>UAR may serve as a valuable, readily available marker that can predict hypertension in NAFLD patients, particularly those with associated diabetes and obesity.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":0.8,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147491955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}